Publications
Publications
- April 1993 (Revised May 1994)
- HBS Case Collection
Genzyme Corporation: Strategic Challenges with Ceredase
Abstract
Genzyme Corp., one of the largest biotechnology companies, has succeeded in developing, manufacturing, and commercializing its first therapeutic, a treatment for a rare genetic disease. Analysis of the case requires students to identify and understand how Genzyme has designed its strategy to effectively manage, mitigate, or exploit the uncertainties it had faced in the past. In 1993, the company faces challenges in managing future uncertainties involving the product's market, manufacturing, and pricing.
Keywords
Risk Management; Risk and Uncertainty; Corporate Strategy; Technology; Health; Product Development; Biotechnology Industry; Pharmaceutical Industry; United States
Citation
Teisberg, Elizabeth O., and Sharon L. Rossi. "Genzyme Corporation: Strategic Challenges with Ceredase." Harvard Business School Case 793-120, April 1993. (Revised May 1994.)